Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, D W Y
Right arrow Articles by Wong, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, D W Y
Right arrow Articles by Wong, J
Topic Collections
Right arrowRelevant Article
Gut 2002;50:869-876
© 2002 by Gut


LIVER DISEASE

Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model

D W Y Ho, S T Fan, J To, Y H Woo, Z Zhang, C Lau, J Wong

Centre for the Study of Liver Disease and Department of Surgery, University of Hong Kong, Hong Kong

Correspondence to:
Correspondence to:
Professor S T Fan, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, 102 Pokfulam Rd, Hong Kong;
hrmsfst{at}hkucc.hku.hk


ABSTRACT
Background: Plasma exchange may be useful for treating patients with fulminant hepatic failure but during the procedure growth factors that are important for hepatic regeneration are discarded. Addition of a selective plasma filter to the plasmapheresis circuit could eliminate protein bound toxic substances and retain growth factors for hepatic regeneration. This process is called selective plasma filtration.

Aims: To determine if selective plasma filtration could be a useful treatment modality for fulminant hepatic failure.

Methods: The system was tested in five groups of pigs with fulminant hepatic failure induced by galactosamine: group I, diseased control group (n=5); group II, sham control, (n=6); group III, plasma exchange (n=6); group IV, treatment with AC-1770 selective plasma filter (n=7); and group V, treatment with AC-1730 selective plasma filter which had a smaller pore size than AC-1770 (n=7). Fresh pig plasma was given to replace filtered plasma in pigs of groups III, IV, and V. Treatment was initiated 48 hours after administration of 0.75 g/kg galactosamine. The efficacy of selective plasma filtration was assessed by survival rate and improvement in haematological, biochemical, and immunohistological parameters.

Results: Pigs treated with AC-1770 or AC-1730 selective plasma filters survived longer than the other groups (group I: 55 (10) hours; group II: 68 (7) hours; group III: 91 (10) hours; group IV: 269 (156) hours; group V: 950 (555) hours). One pig in group IV survived for 50 days; one pig in group V survived for 77 days and another pig in group V is still alive (>150 days). After treatment, plasma levels of aspartate aminotransferase, bilirubin, bile acid, ammonia, lactate dehydrogenase, and {alpha}-glutathione-S-transferase decreased. Substantial amounts of tumour necrosis factor {alpha} (TNF-{alpha}) and endotoxin were found in the filtrate. The selective plasma filtration groups retained significantly higher amounts of hepatocyte growth factor than plasma exchange alone. Similar TNF-{alpha} clearance was observed in the selective plasma filtration groups and the plasma exchange group. On day 4, significant improvement in liver function, as measured by the indocyanine green clearance test, was observed in groups IV and V but not in the other groups. A higher regeneration index of hepatocytes was also observed in the groups treated with AC-1770 and AC-1730 selective plasma filters.

Conclusion: Selective plasma filtration improved survival time and expedited liver regeneration in pigs with fulminant hepatic failure.


Keywords: fulminant hepatic failure; AC-1770; AC-1730; selective plasma filtration; plasma exchange

Abbreviations: HGF, hepatocyte growth factor; ICG, indocyanine green; TNF-{alpha}, tumour necrosis factor {alpha}


Relevant Article

Digest
Ian Forgacs
Gut 2002 50: 743. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Infect. Immun.Home page
M. Harvie, T. W. Jordan, and A. C. La Flamme
Differential Liver Protein Expression during Schistosomiasis
Infect. Immun., February 1, 2007; 75(2): 736 - 744.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
D. W. Ho, Z. F. Yang, C. K. Lau, K. H. Tam, J. Y. To, R. T. Poon, and S. T. Fan
Therapeutic Potential of Cardiotrophin 1 in Fulminant Hepatic Failure: Dual Roles in Antiapoptosis and Cell Repair
Arch Surg, November 1, 2006; 141(11): 1077 - 1084.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 BMJ Publishing Group Ltd & British Society of Gastroenterology